Rigel Pharmaceuticals reported total revenues of $78.7 million for the second quarter, reflecting a 14% increase in net product sales. This growth supports investor confidence as the company anticipates the U.S. launch of VEPPANU, a new treatment expected to further enhance revenue streams.
Key Highlights
- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) announced total revenues of $78.7 million for the second quarter, driven by a 14% year-over-year increase in net product sales to $67.0 million.
- Second quarter revenues consisted of $78.7 million, which included $67.0 million from net product sales and $11.7 million from contract revenue collaborations.
- Rigel has recently bolstered its commercial offerings by in-licensing VEPPANU™ (vepdegestrant), expected to be commercially available by mid-August.
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) announced total revenues of $78.7 million for the second quarter, driven by a 14% year-over-year increase in net product sales to $67.0 million. This performance comes despite reporting earnings per share of $0.44 in the previous quarter, which fell short of the $0.78 consensus estimate. The revenue increase is a positive sign for investors, showcasing Rigel’s growing market presence and potential for sustained profitability.
Q2 Revenue Breakdown
Second quarter revenues consisted of $78.7 million, which included $67.0 million from net product sales and $11.7 million from contract revenue collaborations. The net product sales rose from $58.9 million year-over-year. Notable contributors included TAVALISSE®, which generated sales of $47.4 million, an 18% increase from $40.1 million in the same quarter of the previous year.
Meanwhile, GAVRETO® sales saw a slight decline of 10% to $10.7 million compared to the prior year's $11.8 million. The diverse product lineup is important for Rigel as it enhances its market share in the competitive healthcare sector, particularly in hematology and oncology.
Strategic Expansions
Rigel has recently bolstered its commercial offerings by in-licensing VEPPANU™ (vepdegestrant), expected to be commercially available by mid-August. This FDA-approved PROTAC therapy targets advanced breast cancer in patients who have not responded to prior therapies. The company paid an upfront fee of $70.0 million for this exclusive global licensing deal with Arvinas and Pfizer, signifying Rigel’s commitment to expanding its therapeutic portfolio.
As VEPPANU becomes available, it may attract a new patient demographic and solidify Rigel's reputation as a leader in cancer therapies, leading to potential revenue spikes.
Market Context and Performance Outlook
The current market capitalization stands at approximately $718 million, indicating a solid footing despite the stock's year-long volatility, with a 52-week range between $21.87 and $52.24. As Rigel navigates its growth avenues, including ongoing studies for the R289 development program, investor sentiment remains cautiously optimistic. The upcoming preliminary data expected by the end of the year will be essential for impact on share prices and overall market confidence in Rigel's future endeavors.
What’s Ahead
Investors should keep an eye on the earnings call scheduled for August 4, where management is likely to provide further insights into performance metrics and future expectations, including the anticipated rollout of VEPPANU. With numerous developments on the horizon, this call is a critical event that could influence stock performance moving forward.
Peers Moving on This News
- Aura Biosciences Inc (AURA) little changed
- CytomX Therapeutics Inc (CTMX) down 0.6%
- Climb Bio Inc (CLYM) little changed
Analysis based on the Form 8-K filed 4 August 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...